Helen M. Boudreau

Board Director

Director

Premier, Inc.Cara Therapeutics, Inc.Rallybio Corp

Insider activity · 24 months0 buys2 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 1 saleFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 1 saleJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (3 ops.)

€213k

Latest filing published 10 Jul 2026 for Rallybio Corp, €7,412. Read the official filing

Filing timeline

BuySale

Helen M. Boudreau

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Helen M. Boudreau: trading record in brief

Helen M. Boudreau (board member) discloses dealings in 3 companies, chiefly Premier, Inc., Rallybio Corp and Tvardi Therapeutics, Inc. Over a trading history stretching from 6 December 2021 to 6 July 2026, the count stands at 10 filings.

Sales make up the whole of the open-market record (3 sales, €213k). The rest of the record consists of 5 share grants and 1 option exercise.

The newest entry dates from 10 July 2026: an option exercise of €7,412, in Rallybio Corp. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.